Market news
Ginkgo Bioworks surged on partnership news, but Q2 revenue fell and losses widened as valuation jumps. Click here to read this DNA stock update.
Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $7.06, signifying a +1% move from its prior day's close.
Twist Bioscience (TWST) stock and Ginkgo Bioworks (DNA) stock gain as companies ink agreements with Eli Lilly’s (LLY) TuneLab R&D platform. Read more here.
BOSTON, September 16, 2026--Ginkgo Bioworks (NYSE: DNA) today announced that its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab supports biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data.
BOSTON, September 10, 2026--Ginkgo Bioworks (NYSE: DNA) today announced that it has been awarded a subcontract for up to $17.5M under the Advanced Research Projects Agency for Health’s (ARPA-H) Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. Ginkgo will serve as a subcontractor to prime contractor Waterfall Scientific, Inc. on ESCALATOR (Engineering a Small-scale, Continuous-flow manufacturing Apparatus to Launch A Transformational Overhaul for RNA medicines), a m
Detailed price information for Editas Medicine (EDIT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Ginkgo Bioworks Holdings (DNA-N) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.